Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024 J.M. Remes-Troche; E. Coss-Adame; M. Schmulson; K.R. García-Zermeño; M. Amieva-Balmori; R. Carmona-Sánchez; O. Gómez-Escudero; P.C. Gómez-Castaños; M.E. Icaza-Chávez; A. López-Colombo; E.C. Morel-Cerda; M.Á. Valdovinos-Díaz; L.R. Valdovinos-García; A.S. Villar-Chávez;

Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: An open population study R. Bernal-Reyes; M.E. Icaza-Chávez; L.A. Chi-Cervera; J.M. Remes-Troche; M. Amieva-Balmori; B.A. Priego-Parra; S. Martínez-Vázquez; I.O. Méndez-Guerrero; L. Martínez-Rodríguez; A. Barranca-Enríquez; C. Palmeros-Exsome; A.D. Cano-Contreras; A. Triana-Romero;

Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population M.G. Aja-Cadena; M. Amieva-Balmori; H.A. Taboada-Liceaga; O.J. Cobos-Quevedo; G.A. Hernández-Ramírez; J. Reyes-Huerta; F. Roesch-Dietlen; A. Meixuerio-Daza; J.M. Remes-Troche;